Plaque Psoriasis (Localized)
Investigational use for localized stable plaque psoriasis; small case series suggest plaque thinning. Not a primary treatment.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for plaque psoriasis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for plaque psoriasis is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). Small case reports describe plaque thinning at sites of leech application. There are no randomized controlled trials. Psoriasis has many highly effective evidence-based treatments — topical corticosteroids, vitamin D analogues, phototherapy (UVB, PUVA), and biologics (IL-17, IL-23, TNF inhibitors) — supported by extensive RCT data and guidelines.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness around plaques for 5 to 10 days
- Itching and irritation at bite sites for days to weeks
- Local skin infection or, rarely, Aeromonas infection (heightened with psoriatic skin barrier disruption)
- Koebner phenomenon — new psoriatic plaques forming at bite sites in some patients
- Allergic reaction to leech saliva (uncommon)
- Small permanent scars at bite sites
- Quién no debería considerar esto
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients on systemic immunosuppressants or biologics (higher infection risk)
- Patients with active erythrodermic, pustular, or unstable psoriasis
- Patients with active skin infection
- Patients with extensive disease where topical/systemic treatments are clearly indicated
- Qué preguntar a su clínico
- Have I been evaluated by a dermatologist?
- Have I had adequate trials of topical corticosteroids, vitamin D analogues, phototherapy, or biologics?
- What evidence supports leech therapy for plaque psoriasis specifically?
- What is the risk of Koebner phenomenon (new plaques at bite sites)?
- What is the realistic chance of benefit, and for how long?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- Cuándo buscar atención urgente
- Rapid widespread reddening of skin (possible erythroderma — emergency)
- Spreading pus, redness, warmth, or red streaks (cellulitis, especially with biologic users)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- This is not FDA-cleared for plaque psoriasis.
- Case reports do NOT establish efficacy versus evidence-based topical, phototherapy, or biologic therapies.
- Mechanism rationale does NOT establish clinical efficacy.
- Leech bites may trigger the Koebner phenomenon — new psoriasis plaques at bite sites.
- Leech therapy is not a substitute for dermatology evaluation and standard psoriasis care.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- dermatological
- ICD-10
- L40.0, L40.4, L40.8
- Safety tier
- medium
Evidence Summary
No controlled clinical trial or credible case series of leech therapy for plaque psoriasis has been published; there is no reliable evidence that it reduces PASI scores or thins plaques. Any proposed local immunomodulatory mechanism is speculative and unproven. Generalized psoriasis is not appropriate for leech therapy, and standard care (topical corticosteroids, vitamin D analogues such as calcipotriol, phototherapy, and systemic or biologic agents including methotrexate for moderate-to-severe disease) remains the standard. The Koebner phenomenon (new lesions provoked at sites of skin trauma) is a genuine theoretical concern with any skin-breaking procedure. ASH position: any use of leech therapy for psoriasis is investigational and mechanistic only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Ashraf S et al. (2014), n=15
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Erythrodermic or generalized pustular psoriasis
- Active concomitant biologic therapy
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.